Pain-targeted Nurofen tablets taken off shelves in Australia

 

An Australian court ruled the products marketed to treat specific pains, such as migraine and period pains, were identical to one another - and therefore misled consumers.

It said that British-based multinational had made misleading claims about its Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache products

It follows the Australian Competition and Consumer Commission (ACCC) taking the company to court in March.

It was found the active ingredient, ibuprofen lysine 342mg, was the same in each of the products, and each product had the same effect on pain. 

Nurofen said the products had been 'designed to help the consumer easily navigate our range', especially in stores where there was no pharmacy.